Israel's IceCure Medical 2025 gross margin falls to 36% on higher costs

Overview

• Israel cryoablation device maker's 2025 revenue rose, driven by global sales growth

• Gross margin for 2025 declined to 36% from 44% yr/yr, due to higher costs

• Net loss for 2025 narrowed

Outlook

• Company expects to on-board 30 hybrid commercial-clinical sites in U.S. for post-marketing study in 2026

• IceCure expects expanded reimbursement coverage for low-risk breast cancer procedures in U.S.

Result Drivers

• PROSENSE ADOPTION - Record sales driven by increased global and U.S. adoption of ProSense following FDA clearance and new medical society guidelines

• REGIONAL SALES MIX - Sales growth in Europe, Latin America, North America, and China offset by lower sales in Japan

• HIGHER COSTS - Gross margin declined due to increased costs for raw materials, subcontractors, auxiliary materials, and payroll

Company press release: ID:nPn4znbfla

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Icecure Medical Ltd is $3.13, about 328.1% above its March 16 closing price of $0.73

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.